Table 9. Treatment strategies for newly-diagnosed peripheral T-cell lymphoma.

Histological type	Stage	Category I recommendations	Category II recommendations
AITL, angioimmunoblastic T-cell lymphoma; ALCL, ALK−, ALK-negative anaplastic large cell lymphoma; ALCL, ALK+, ALK-positive anaplastic large cell lymphoma; ASCT, autologous stem cell transplantation; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CHP, cyclophosphamide, doxorubicin and prednisone; DA-EPOCH, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin; ISRT, involved-site radiotherapy PTCL, peripheral T-cell lymphoma; PTCL-NOS, PTCL-not otherwise specified.
ALCL, ALK+	I−II	CHOEP ± ISRT (Level 1A evidence) CHOP ± ISRT (Level 2A evidence) DA-EPOCH (Level 2A evidence)	Brentuximab vedotin + CHP (Level 2A evidence)
	III−IV	CHOEP (Level 1A evidence) CHOP (Level 2A evidence) DA-EPOCH (Level 2A evidence)	ASCT (high risk patients) (Level 2A evidence) Brentuximab Vedotin + CHP (Level 2A evidence)
PTCL-NOS AITL ALCL, ALK−		Clinical trial CHOEP ± ISRT (Level 1A evidence) CHOP ± ISRT (Level 2A evidence) DA-EPOCH (Level 2A evidence) ASCT (Level 2A evidence)	Brentuximab Vedotin + CHP (ALK-ALC) (Level 2A evidence)